An Israeli health worker of the Maccabi Healthcare Services prepares to administer a dose of the Pfizer-BioNtech vaccine on February 24, 2021 in Tel Aviv.
Jack Guez | AFP | Getty Images
The coronavirus variant first discovered in South Africa is able to evade some of the protection of the Pfizer–BioNTech vaccine, according to a new Israeli study, which has not yet been peer-reviewed.
Researchers at Tel Aviv University and Clalit, the largest health-care organization in Israel, examined nearly 400 people who had tested positive for Covid-19 after receiving at least one dose of the vaccine. They compared them to the same number of people who were infected and unvaccinated.